Biotechnology Royalty Agreements Law In Russia.
1. Introduction
Biotechnology royalty agreements in Russia are legal arrangements under which a biotechnology company, research institution, university, inventor, patent owner, or pharmaceutical manufacturer receives financial compensation for permitting another party to use protected biotechnology intellectual property.
These agreements are particularly important in the Russian biotechnology sector because commercial biotechnology depends on licensing patents, genetic-engineering technologies, pharmaceutical inventions, recombinant proteins, vaccines, biological materials, diagnostic methods, and research technologies.
A royalty agreement generally provides that a licensee pays the intellectual-property owner a specified amount or percentage of revenue in exchange for authorized use of the licensed technology.
Russia does not have one separate statute exclusively governing biotechnology royalty agreements. Instead, the principal legal framework is found in Part IV of the Civil Code of the Russian Federation, together with pharmaceutical, biotechnology, competition, tax, and contractual regulations.
The central legal objective is to balance:
Protection of biotechnology inventions.
Fair remuneration for inventors and patent holders.
Commercial exploitation of scientific discoveries.
Protection of confidential research information.
Prevention of unauthorized use of patented technology.
Regulation of technology transfers and licensing arrangements.
Fair distribution of commercial revenues between research institutions and biotechnology companies.
2. Legal framework governing biotechnology royalty agreements
The principal legislation is the Civil Code of the Russian Federation, Part IV (Intellectual Property Law).
The following provisions are particularly relevant.
| Legal provision | Subject | Application to biotechnology |
|---|---|---|
| Article 1225 | Protected intellectual property | Establishes categories of protected intellectual property |
| Article 1229 | Exclusive rights | Protects the rights of biotechnology patent holders |
| Article 1233 | Disposal of exclusive rights | Permits licensing and transfer of biotechnology rights |
| Article 1235 | Licence agreements | Establishes the principal rules for royalty contracts |
| Article 1236 | Types of licences | Regulates exclusive and non-exclusive licensing |
| Article 1237 | Performance of licence agreements | Governs royalty payment, reporting and compliance |
| Article 1238 | Sublicensing | Permits authorized sublicensing |
| Article 1239 | Compulsory licensing | Provides for court-ordered licences in legally specified circumstances |
| Article 1357 | Right to obtain a patent | Determines entitlement to patent ownership |
| Article 1367 | Patent licence agreements | Specifically governs licensing of patented inventions |
| Article 1368 | Open patent licences | Provides a mechanism for making patent rights available to interested parties |
| Article 1362 | Compulsory patent licensing | Addresses non-use and certain dependent-invention situations |
These provisions establish that biotechnology royalty arrangements are primarily governed by intellectual-property licensing principles.
USPTO+2
3. Meaning and legal nature of royalty agreements
A biotechnology royalty agreement is generally a licence agreement under which the patent owner authorizes another party to use a protected invention in return for financial remuneration.
For example:
A Russian biotechnology research institute develops a patented recombinant-protein manufacturing process. A pharmaceutical company wants to manufacture medicines using that process.
The parties may enter into a royalty agreement under which:
The research institute remains the patent owner.
The pharmaceutical company receives permission to use the patented technology.
The company pays an agreed royalty.
The company submits periodic reports concerning licensed production and sales.
The institute retains its contractual and statutory enforcement rights.
The agreement does not automatically transfer ownership of the patent. It grants only the rights expressly specified in the contract.
Important distinction: A royalty agreement is not necessarily a transfer of intellectual property. A licence permits authorized use, whereas an assignment under Article 1365 transfers the patent's exclusive right in full.
4. Types of biotechnology royalty agreements
A. Patent royalty agreements
These agreements concern patented biotechnology inventions, including:
Gene-editing technologies.
Recombinant DNA techniques.
Vaccine-production processes.
Biopharmaceutical manufacturing methods.
Diagnostic technologies.
Genetically engineered microorganisms.
Article 1367 provides the specific legal basis for patent licensing.
B. Pharmaceutical biotechnology royalty agreements
These agreements cover patented biological medicines, therapeutic proteins, vaccines, and other biotechnology-based pharmaceutical inventions.
The royalty may be calculated using the licensee's sales of the licensed pharmaceutical product.
However, the patent licence does not itself replace the necessary pharmaceutical registration, manufacturing authorization, or other regulatory approvals.
C. Research and university licensing agreements
Russian universities and research institutions may license inventions developed by researchers or through institutional research programmes.
The agreement should identify:
Ownership of the invention.
Inventor recognition.
Institutional intellectual-property rights.
Commercialization responsibilities.
Royalty-sharing arrangements.
Rights to future improvements.
D. Know-how royalty agreements
Some biotechnology processes are protected as confidential production secrets rather than patents.
Examples include:
Fermentation conditions.
Cell-culture protocols.
Biological purification methods.
Manufacturing parameters.
Proprietary laboratory techniques.
Article 1465 of the Civil Code provides the legal framework for production secrets (know-how). Article 1469 governs their licensing.
E. Software and algorithm royalty agreements
Biotechnology companies may also license software, bioinformatics tools, genomic-analysis programmes, and proprietary research databases.
Depending on the protected subject matter, copyright and other intellectual-property provisions may apply.
5. Royalty calculation and payment mechanisms
Article 1235(5) recognizes several ways to calculate licence remuneration.
| Royalty structure | Explanation | Biotechnology example |
|---|---|---|
| Fixed payment | One-time payment | Payment for initial technology access |
| Periodic payment | Monthly or annual payment | Annual licence fee for laboratory technology |
| Percentage royalty | Percentage of revenue | 5% of net sales of a licensed biological medicine |
| Milestone payment | Payment upon achieving agreed targets | Payment after successful clinical-development milestones |
| Hybrid arrangement | Combination of payment methods | Initial fee plus sales-based royalties |
The percentage figures above are illustrative commercial examples, not statutory Russian royalty rates.
A particularly important legal rule: Under Article 1235(5), a paid licence agreement must specify either the amount of remuneration or a method for determining it. If it does not, the agreement is treated as not concluded. The general rules for determining contractual prices cannot simply fill this omission.
Consequently, a biotechnology royalty agreement should clearly define the royalty base, calculation formula, reporting period, payment deadlines, currency, deductions, and treatment of refunds and discounts.
kodeks.karelia.ru+1
6. Registration and formal requirements
Russian biotechnology royalty agreements must satisfy important contractual and registration requirements.
A. Written agreement
Article 1235(2) requires a written licence agreement. Failure to comply with the required written form makes the agreement invalid.
B. Identification of intellectual property
The agreement should identify the licensed patent or other protected intellectual property precisely.
For patented biotechnology, this normally includes:
Patent number.
Patent title.
Patent holder.
Relevant claims or protected invention.
Licensed manufacturing or research activities.
C. Territorial scope
Article 1235(3) requires the agreement to specify the territory in which the licensed technology may be used. If the territory is not specified, the licence generally extends throughout the Russian Federation.
D. Duration
Under Article 1235(4), the licence cannot exceed the duration of the underlying exclusive right. If no contractual duration is specified, the statutory default is generally five years, subject to the duration of the exclusive right.
E. State registration
Under Articles 1232 and 1369, granting rights to use a registered patent is subject to state registration. The relevant formalities are handled through Rospatent.
Failure to satisfy a mandatory registration requirement means that the grant of the right to use the patent is deemed unaccomplished.
USPTO+2
7. Important Russian case laws and judicial decisions
Russian courts have not established a large, independent body of biotechnology royalty decisions. Nevertheless, pharmaceutical biotechnology patent disputes and judicial interpretations of licensing law provide important precedents.
The following decisions are particularly relevant.
Case 1. Nativa LLC v. Celgene Corporation – Case No. A40-71471/2017
Important compulsory-licensing precedent
Subject: Lenalidomide pharmaceutical patent and compulsory licensing.
The dispute concerned the Russian patent rights associated with lenalidomide, a pharmaceutical substance used in cancer treatment.
Nativa sought a compulsory non-exclusive licence to use technology protected by Celgene's patent.
The litigation raised questions concerning:
Whether the patent was being sufficiently exploited.
Whether the applicant was capable of commercial production.
Whether the patent holder could refuse voluntary licensing.
Whether a compulsory licence could be granted on commercially reasonable terms.
How royalty payments should be determined.
The initial court proceedings resulted in a compulsory licensing arrangement with remuneration calculated using a sales-related formula.
However, the later legal history is important: the underlying patent was subsequently challenged, and the compulsory licensing arrangement was affected by developments concerning patent validity and settlement.
Legal significance: The dispute demonstrates that pharmaceutical biotechnology patent owners may face compulsory licensing where statutory conditions are satisfied. It also shows that royalty obligations depend on the continuing legal status of the underlying patent.
Law Gratis+2
Case 2. Vertex Pharmaceuticals v. MIK – Case No. A40-185112/2022 (2023)
Significant pharmaceutical licensing decision
Subject: Compulsory licensing of patents relating to Trikafta.
The dispute involved Vertex patents concerning the medicines associated with ivacaftor, tezacaftor and elexacaftor, used in treating cystic fibrosis.
Russian pharmaceutical company MIK sought compulsory licences under Article 1362(1) of the Civil Code.
On 25 September 2023, the Ninth Commercial Court of Appeal ordered the granting of non-exclusive licences.
The court considered evidence concerning:
Insufficient availability of patented medicines.
Actual demand from patients.
The availability of alternative supply.
The applicant's ability to manufacture or supply equivalent medicines.
The requirements for compulsory licensing.
Legal significance for royalty agreements:
This decision demonstrates that patent exclusivity is subject to statutory limitations. A biotechnology patent holder cannot assume that refusing commercial licensing will always prevent competitors from obtaining lawful access to patented technology.
The case also illustrates the importance of determining appropriate remuneration and the scope of licensed rights.
lidings.com+1
Case 3. Constitutional Court of the Russian Federation – Judgment No. 13-П of 12 March 2026
Important 2026 judicial development
Subject: Constitutionality of Article 1362 and compulsory licensing for medicinal products.
The Constitutional Court examined Article 1362(1) and (2) insofar as they concern compulsory licences for inventions used in the production and supply of medicines.
The Court recognized that compulsory licensing may be constitutionally permissible when necessary to protect public interests, including access to essential medicinal products.
Its approach emphasizes that courts must consider:
Actual demand in the Russian market.
The shortage of relevant medicinal products.
The applicant's ability to manufacture or supply products of the required quality.
The legitimate interests of patent holders.
Appropriate licence remuneration.
The scope and duration of the compulsory licence.
The Court also emphasized that the licence should be limited to the extent justified by the actual market need.
Legal significance: The decision is especially relevant to biotechnology royalty arrangements involving vaccines, biological medicines, therapeutic proteins and other important pharmaceutical inventions.
It reinforces the principle that patent protection and public access to medicines must be considered together, while ensuring appropriate compensation for the patent holder.
ksrf.ru+1
Case 4. Joint Resolution No. 5/29 of 26 March 2009 – Supreme Court and Supreme Arbitration Court
Subject: Judicial interpretation of intellectual-property licensing agreements.
This joint resolution provides important guidance on Articles 1234 and 1235.
The courts clarified that:
Licensing agreements must comply with the prescribed written-form requirements.
Mandatory state registration requirements must be respected.
A paid licence agreement must establish the remuneration amount or a method for determining it.
A licence agreement that omits the necessary remuneration provisions may be treated as not concluded.
Royalty payment is generally due for the grant of the licensed right, rather than being automatically dependent on actual commercial use.
The interpretation is particularly significant for biotechnology contracts in which the parties negotiate fixed payments, periodic royalties or revenue-based remuneration.
Legal significance: A biotechnology licensee cannot automatically avoid agreed royalties merely by arguing that it did not commercially exploit the licensed technology.
WIPO+1
Case 5. Second Cassation Court of General Jurisdiction – 1 April 2025, Case No. 8Г-2142/2025
Subject: Patent licence obligations and contractual remuneration.
The court referred to Articles 1235 and 1367 of the Civil Code and the general contractual performance requirement under Article 309.
The decision emphasized that a patent licence creates an obligation to pay the agreed remuneration and that contractual obligations must be properly performed.
Legal significance: The reasoning is relevant to biotechnology licensing disputes involving unpaid royalties, patent-use authorization and enforcement of agreed financial obligations.
ГАРАНТ
8. Compulsory licensing and biotechnology royalty payments
Compulsory licensing is an important limitation on exclusive biotechnology patent rights.
Under Article 1362(1), a court may grant a compulsory non-exclusive licence when:
A patented invention has not been used or has been insufficiently used for four years after patent grant.
The lack of use results in insufficient supply of relevant goods, works or services.
An interested party is willing and ready to use the invention.
The patent holder refuses to enter into a licence agreement on terms consistent with established practice.
The statutory conditions are established before the court.
The court determines the licence conditions, including the amount, procedure and timing of payments. The total remuneration must not be below the comparable licence price.
Article 1362(2) also addresses dependent inventions. This can be relevant where a biotechnology innovation cannot be exploited without using an earlier patented invention.
The compulsory licence does not ordinarily transfer patent ownership. The original patent holder retains its exclusive right, subject to the compulsory licence.
kodeks.karelia.ru+2
9. Competition law and royalty agreements
Federal Law No. 135-FZ of 26 July 2006, On Protection of Competition, is relevant to biotechnology royalty arrangements.
Potential competition issues include:
Excessive licensing restrictions.
Unlawful refusal to license essential technology.
Restrictive exclusive licensing arrangements.
Discriminatory royalty structures.
Agreements that restrict market competition.
Abuse of a dominant market position.
For example, suppose a biotechnology patent owner controls an important technology required for manufacturing a particular biological medicine.
If the patent owner uses licensing conditions to unlawfully exclude competitors or restrict competition, the arrangement may attract scrutiny under Russian competition law.
However, exclusive licensing and differentiated royalty rates are not automatically unlawful. Their legality depends on the contractual circumstances and applicable competition rules.
10. Confidentiality and protection of biotechnology know-how
Biotechnology royalty agreements frequently include confidential scientific and manufacturing information.
Examples include:
Genetic-engineering protocols.
Cell-line development procedures.
Fermentation methods.
Protein purification techniques.
Laboratory testing procedures.
Manufacturing specifications.
Article 1465 protects qualifying production secrets (know-how).
Federal Law No. 98-FZ of 29 July 2004, On Commercial Secrets, also provides relevant protection.
A properly drafted royalty agreement should contain confidentiality obligations, restrictions on disclosure, employee-access requirements and procedures for returning or destroying confidential information after termination.
Importantly, information does not automatically qualify as protected know-how merely because a contract describes it as confidential. The statutory conditions for trade-secret protection must be satisfied.
11. International biotechnology royalty agreements
Russia-based biotechnology companies may enter into royalty arrangements with foreign pharmaceutical manufacturers, research institutions, patent owners and technology providers.
Such agreements can involve:
International patent licensing.
Cross-border technology transfers.
Foreign currency payments.
Tax withholding.
Transfer pricing.
Export-control requirements.
Confidentiality and scientific-data transfers.
International commercial arbitration.
Parties should distinguish between contractual territorial rights and patent protection in individual countries. A Russian patent does not automatically provide patent protection in every foreign jurisdiction.
International transactions may also require examination of applicable sanctions, banking restrictions, currency regulations and export-control legislation.
12. Essential clauses in a Russian biotechnology royalty agreement
A legally sound agreement should contain the following provisions:
| Contractual clause | Legal purpose |
|---|---|
| Identification of technology | Identifies the licensed invention |
| Patent ownership | Establishes the licensor's legal entitlement |
| Licence scope | Defines permitted activities |
| Exclusivity | Determines whether other licensees are permitted |
| Territory | Specifies geographical coverage |
| Duration | Determines the licensing period |
| Royalty formula | Establishes the remuneration mechanism |
| Payment schedule | Establishes payment deadlines |
| Audit rights | Permits verification of royalty calculations |
| Reporting obligations | Requires production and sales information |
| Know-how protection | Protects confidential technology |
| Improvements | Allocates rights in future developments |
| Regulatory compliance | Allocates pharmaceutical and manufacturing responsibilities |
| Indemnification | Allocates contractual liabilities |
| Termination | Defines circumstances for ending the agreement |
| Dispute resolution | Establishes the procedure for resolving disputes |
Example of a royalty calculation
Assume a Russian biotechnology company licenses a patented biological medicine manufacturing process.
Illustrative commercial arrangement
Annual net sales
₽100 million
Agreed royalty rate
5%
Annual royalty payable
₽5 million
\[ 100,000,000\times 5\%=5,000,000 \]
Illustrative example only; not a legally prescribed Russian royalty rate.
13. Legal remedies for breach of royalty agreements
Where a biotechnology licensee fails to fulfil its contractual obligations, the patent owner may have several remedies.
A. Recovery of unpaid royalties
The licensor may bring a contractual claim for unpaid remuneration.
B. Contract termination
Under Article 1237(4), where the licensee materially breaches its obligation to pay remuneration, the licensor may unilaterally withdraw from the licence agreement and claim damages. The agreement terminates after the statutory 30-day period following notification if the breach remains uncured.
C. Patent infringement proceedings
Under Article 1237(3), use outside the authorized contractual scope or after termination can constitute infringement of exclusive rights.
D. Damages and other remedies
Depending on the circumstances, the patent owner may seek compensation, damages, contractual penalties and other remedies available under Russian civil law.
E. Dispute resolution
Commercial disputes between business entities will generally fall within the jurisdiction of the Russian state commercial courts (arbitrazh courts), subject to applicable jurisdiction and arbitration agreements.
14. Relationship with other Russian biotechnology legislation
Several additional statutes may affect the commercial operation of biotechnology royalty agreements.
| Legislation | Relevance |
|---|---|
| Federal Law No. 86-FZ of 1996 | State regulation of genetic engineering activities |
| Federal Law No. 61-FZ of 2010 | Circulation of medicinal products |
| Federal Law No. 135-FZ of 2006 | Competition restrictions and market dominance |
| Federal Law No. 98-FZ of 2004 | Commercial-secret protection |
| Federal Law No. 180-FZ of 2016 | Biomedical cell products |
| Federal Law No. 323-FZ of 2011 | Protection of citizens' health and medical activities |
These statutes operate alongside the Civil Code. A biotechnology royalty agreement cannot override mandatory pharmaceutical safety, licensing, manufacturing or research requirements.
15. Critical legal issues and challenges
The Russian biotechnology royalty system raises several important legal questions.
1. Ownership of university inventions
Disputes may arise between researchers, universities, research sponsors and commercial biotechnology companies over ownership and entitlement to royalty income.
2. Uncertain commercial valuation
Biotechnology inventions may require substantial investment before generating revenue. Determining a reasonable royalty can therefore be difficult.
3. Patent validity
A royalty arrangement may be affected if the underlying patent is invalidated or its protection is terminated.
4. Research and commercial-use distinction
A licence for laboratory research should not automatically be interpreted as authorization for commercial manufacturing.
5. Improvements and derivative inventions
The agreement should clarify ownership and royalty treatment of improvements developed by the licensee.
6. Access to essential medicines
Compulsory licensing can create tension between patent owners' remuneration rights and public access to pharmaceutical biotechnology products.
7. International payment difficulties
Cross-border royalty transactions may encounter banking, currency, tax and sanctions-related restrictions.
16. Conclusion
Biotechnology royalty agreements in Russia are principally governed by Part IV of the Civil Code, particularly Articles 1235, 1236, 1237, 1238, 1362 and 1367.
The legislation provides a contractual framework for licensing patents, transferring technological knowledge and receiving remuneration for commercial exploitation of biotechnology inventions.
Russian judicial decisions, particularly the Nativa–Celgene litigation, the Vertex–MIK compulsory licensing dispute and Constitutional Court Judgment No. 13-П of 12 March 2026, demonstrate the importance of balancing patent-holder remuneration with competition, pharmaceutical availability and public interests.
For biotechnology businesses, the most important legal requirements are accurate identification of licensed intellectual property, a clearly defined royalty formula, compliance with registration requirements, proper reporting, confidentiality protection and appropriate allocation of commercial and regulatory risks.
The overall legal principle is that biotechnology innovation can be commercially exploited through licensing, but the rights of patent holders, contractual obligations and mandatory public-interest regulations must all be respected.
17. Important legal sources and further reading
Russian Civil Code, Part IV – Rospatent official text (2025 edition).
Supreme Court Plenum guidance on intellectual-property disputes.
Russian Constitutional Court – compulsory licensing principles.
Vertex–MIK compulsory licensing case, 2023.
Moscow Commercial Court – Case A40-185112/2022.
Joint Resolution No. 5/29 of 26 March 2009.
Research note: The cited judicial decisions concern pharmaceutical patents and general intellectual-property licensing, rather than a separate category of biotechnology royalty agreements. Their relevance is by legal analogy. For litigation or contract execution, the full judgments, subsequent procedural history and legislation effective on the transaction date should be checked.

comments